Skip to main content
TipRanks
Go Ultimate75% OFF

Stemcell United Ltd. (OSS) AI Stock Analysis

1 Followers
AU:OSS

Stemcell United Ltd.

(ASX:OSS)

Select Model
Rating:42Neutral
Price Target:AUD 0.01â–²(0.00% Upside)
Action:reiterated
Date:11/13/26

The score is primarily constrained by weak financial performance—negative gross profit, ongoing losses, negative equity, and continued cash burn—despite a rebound in revenue. Technical indicators also lean bearish (below DMA20 with negative MACD), while valuation is inconclusive due to a negative P/E and no dividend yield data.

Positive Factors
Revenue reboundFY2026 revenue rose to about A$3.44M from A$0.35M, indicating materially stronger commercial activity and potential product traction. If retained, this larger revenue base could improve operating leverage and provide a foundation for scaling the business over the next several quarters.
Negative Factors
Unprofitable operationsNegative gross profit and a net margin near -52% show that the company has not yet demonstrated an economically sustainable business model. Without a durable improvement in pricing, costs, or product mix, higher revenue may not translate into earnings or internally generated capital.

Stemcell United Ltd. (OSS) vs. iShares MSCI Australia ETF (EWA)

-60%-40%-20%0%20%40%AU:OSS-45.00%EWA+14.75%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 3.13M
Dividend Yield
―
Average Volume (3M)
528.43K
Price to Earnings (P/E)
-3.2
Beta (1Y)
-0.65
Revenue Growth
877.51%
EPS Growth
67.42%
Country
Australia
Employees
31
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Stemcell United Ltd. Business Overview & Revenue Model

Company Description

Ocean Sciences Ltd. is a plant-based biotechnology company, which engages in the business of sourcing, producing, marketing, and selling traditional medicines. The company was founded by Ian Douglas Christiansen on July 25, 1984 and is headquartered...

Stemcell United Ltd. Financial Statement Overview

Summary

Despite a sharp revenue rebound in FY2026 (~A$3.44M vs ~A$0.35M in FY2025), overall financial quality remains weak: negative gross profit, persistent operating losses (net margin ~-52%), negative shareholders’ equity across FY2024–FY2026, and continued cash burn (FY2026 operating/free cash flow about -A$2.14M). These factors indicate ongoing funding dependence and elevated financial risk.

Income Statement

18Very Negative

Balance Sheet

22Negative

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue3.44M3.44M352.38K109.97K33914.35M
Gross Profit-890.49K-890.49K-678.01K18.27K3392.29M
EBITDA-1.76M-1.76M-1.45M-1.76M-3.52M-2.49M
Net Income-1.79M-1.79M-1.49M-2.27M-4.32M-3.54M
Balance Sheet
Total Assets1.38M1.38M541.00K691.84K2.10M7.16M
Cash, Cash Equivalents and Short-Term Investments259.88K259.88K152.74K134.82K1.14M685.56K
Total Debt555.74K555.74K0508.64K01.30M
Total Liabilities2.26M2.26M2.01M1.97M1.19M2.44M
Stockholders Equity-868.82K-868.82K-1.45M-966.82K530.13K3.20M
Cash Flow
Free Cash Flow-2.14M-2.14M-932.18K-1.26M-1.49M-4.93M
Operating Cash Flow-2.14M-2.14M-929.81K000
Investing Cash Flow-8,382-8,382-2,366185.33K6,291-914.21K
Financing Cash Flow2.44M2.44M962.99K697.04K1.38M281.27K

Stemcell United Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:OSS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:MSBAU:MSB70OutperformAUD 2.29B-26.11-10.06%―555.67%49.08%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:OCCAU:OCC44NeutralAUD 155.26M-10.47-36.83%―51.07%-47.63%
AU:CYPAU:CYP43NeutralAUD 4.35M-0.33-617.89%――13.67%
AU:OSSAU:OSS42NeutralAUD 3.13M-3.17216.63%―877.51%67.42%
AU:1AIAU:1AI40UnderperformAUD 18.25M-5.14-132.20%――-200.00%
AU:CMBAU:CMB39UnderperformAUD 10.30M-1.39-247.44%―-4.24%33.39%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%AU:OSSAU:CYPAU:1AIAU:MSBAU:OCCAU:CMBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:OSS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:OSSStemcell United Ltd.0.01-0.01-45.00%
AU:CYPCynata Therapeutics Limited0.01-0.23-94.56%
AU:1AILiving Cell Technologies Ltd.0.01-0.00-16.67%
AU:MSBMesoblast Limited1.76-0.54-23.48%
AU:OCCOrthocell Ltd0.57-0.50-46.73%
AU:CMBRegeneus Ltd.0.35-0.16-31.37%

Stemcell United Ltd. Corporate Events

Matthew Leonard Ceases as Substantial Holder of Ocean Sciences

Nov 13, 2026

Ocean Sciences Ltd is the company named in the filing; the text does not provide information about its industry, products or market focus.The filing records Matthew Leonard’s cessation as a substantial holder on 11 November 2026 and identifies diluti...

Ocean Sciences Announces Issue of 48,981,817 Ordinary Shares

Nov 11, 2026

Ocean Sciences Ltd (ASX: OSS) announced the issue of 48,981,817 ordinary shares on 11 November 2026. The company said its notice under section 708A(5) means sales of those securities will fall within the exemption from disclosure restrictions under t...

Ocean Sciences Proposes Issue of 10.5 Million Options

Nov 3, 2026

Ocean Sciences Ltd. announced a proposed placement of 10.5 million options, with an exercise price of $0.03 and expiry three years from issue. The proposed securities issue is scheduled for 24 December 2026 and represents a planned capital-markets tr...

Ocean Sciences Proposes Placement of Shares and Options

Nov 3, 2026

Ocean Sciences Ltd (ASX: OSS) is identified as the issuer, but the release provides no information about its industry, primary products, services or market focus.The company announced a proposed placement comprising up to 63,636,364 fully paid ordina...

Ocean Sciences secures $700,000 placement for seaweed expansion

Nov 3, 2026

Ocean Sciences Ltd, a commercial seaweed supply, research and development company, has secured firm commitments for a $700,000 placement at $0.011 per share. Investors will receive one attaching option per share, exercisable at $0.03 for three years,...

Ocean Sciences launches direct seaweed exports to China and secures Takalar lease extension

Oct 30, 2026

Ocean Sciences Ltd reported a pivotal September quarter, highlighted by the start of direct raw seaweed exports to China via its Indonesian subsidiary after securing regulatory approval under the Indonesia–China Mutual Recognition Arrangement. The co...

Ocean Sciences Advances Seaweed Bio-Fertiliser R&D and Maps Commercial Pathways

Oct 21, 2026

Ocean Sciences Ltd is advancing its seaweed-based bio-fertiliser program with Temasek Polytechnic, moving from earlier formulation work to validating and optimising extraction protocols from red, green and brown seaweeds. The current phase aims to de...

Ocean Sciences makes first Spinosum seaweed sale to China, broadening carrageenan reach

Oct 20, 2026

Ocean Sciences has secured its first commercial sale of Eucheuma spinosum seaweed to China, marking a strategic expansion beyond its traditional focus on Kappaphycus alvarezii, or Cottonii. The 25-metric-tonne shipment to existing customer Greenwich...

Ocean Sciences Signs MOU to Build Indonesia–Australia Seaweed Value Chain

Oct 19, 2026

Ocean Sciences Ltd has signed a non-binding Memorandum of Understanding with the Australia-Indonesia Centre to develop an Indonesia–Australia seaweed value chain partnership. The collaboration initially targets value-added seaweed products processed...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026